Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Journal of Cancer Research and Clinical Oncology
Jun GuanElena I Braicu

Abstract

The impact of angiogenesis on long-term survival of high-grade serous ovarian cancer (HGSOC) patients remains unclear. This study investigated whether angiogenic markers correlated with 5-year progression-free survival (PFS) in a large cohort of matched advanced HGSOC tissue samples. Tumor samples from 124 primary HGSOC patients were retrospectively collected within the Tumor Bank Ovarian Cancer ( http://www.toc-network.de ). All patients were in advanced stages (FIGO stage III-IV). No patient had received anti-angiogenesis therapy. The cohort contains 62 long-term survivors and 62 controls matched by age and post-surgical tumor residuals. Long-term survivors were defined as patients with no relapse within 5 years after the end of first-line chemotherapy. Controls were patients who suffered from first relapse within 6-36 months after primary treatment. Samples were assessed for immunohistochemical expression of vascular endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Expression profiles of VEGFA and VEGFR2 were compared between the two groups. Significant correlation between VEGFA and VEGFR2 expression was observed (p < 0.0001, Spearman coefficient 0.347). A high expression of VEGFR2 (VEGFR2high) was found more...Continue Reading

References

Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold F Dvorak
Dec 12, 2003·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Jeffrey D SeidmanBrigitte M Ronnett
Sep 14, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M R RaspolliniG L Taddei
Oct 12, 2004·Biochemical and Biophysical Research Communications·Antoine AlamJean-Marc Herbert
Nov 23, 2005·Oncology·Napoleone Ferrara
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 24, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B C SanchezB K Linderholm
Jul 16, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elena-Ioana BraicuChristina Fotopoulou
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Jan 26, 2012·JAMA : the Journal of the American Medical Association·Kelly L BoltonUNKNOWN Cancer Genome Atlas Research Network
Jun 16, 2012·Virchows Archiv : an International Journal of Pathology·Emma WilliamsSuha Deen
Nov 10, 2012·Critical Reviews in Oncology/hematology·Bradley J MonkIvor Benjamin
Dec 13, 2012·European Journal of Human Genetics : EJHG·K DanzaS Tommasi
Sep 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas du BoisPhilipp Harter
Aug 6, 2015·Obstetrics and Gynecology·Rosemary D CressGary S Leiserowitz
Oct 24, 2015·Nature Reviews. Cancer·David D BowtellFrances R Balkwill
Nov 26, 2015·Nature·David Holmes
Jul 13, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naoki HorikawaIkuo Konishi
Dec 2, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara M NorquistElizabeth M Swisher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.